马萨诸塞州癌症中心2008年与2013年皮肤癌筛查与治疗费用比较
该研究对比了某学术癌症中心2008年与2013年皮肤癌相关医疗(筛查与治疗)费用,总年费用增加64%,接受治疗患者数增加45%,人均治疗费用增加13%。筛查费用占比分别为17%和16%。黑色素瘤人均费用增幅最大(84%),2013年使用伊匹木单抗的少数患者(n=48,占黑色素瘤患者4%)占黑色素瘤治疗费用的42%和皮肤癌相关总费用的20%。局限性为处方费用数据不可得。
要点
- 皮肤癌相关总年费用2008年至2013年增加64%,治疗患者数增加45%,人均治疗费用增加13%。
- 黑色素瘤人均费用增幅最大(84%),2013年伊匹木单抗使用者(n=48,占4%)占黑色素瘤治疗费用的42%。
- 筛查费用占总年费用比例2008年为17%,2013年为16%。
核心结论
- 黑色素瘤费用因伊匹木单抗的引入而增加;需要在国家层面持续开展研究以监测皮肤癌相关医疗的费用效果。
研究设计与样本
- 研究查询了某学术癌症中心2008年和2013年按国际疾病分类第九版皮肤癌相关编码的费用数据(保险与患者支付),并通过相关现行操作术语编码将筛查费用与治疗费用分开。
主要发现
- 皮肤癌相关总年费用增加64%,接受皮肤癌相关医疗的患者数增加45%,人均治疗费用增加13%。
- 筛查占总年费用比例2008年为17%,2013年为16%。
- 黑色素瘤人均费用增加84%,为各皮肤癌诊断中增幅最大。
- 2013年接受伊匹木单抗治疗的少数黑色素瘤患者(n=48,占黑色素瘤患者的4%)占黑色素瘤治疗费用的42%和皮肤癌相关医疗费用的20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 处方费用数据不可得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Temporal analyses of skin cancer costs are needed to examine how expenditure differences between diagnoses are changing. OBJECTIVE: To tabulate the costs of skin cancer-related care (SCRC), including both screening and treatment, at an academic cancer center at 2 time points. METHODS: Cost data (insurance and patient payments) at an academic cancer center from 2008 and 2013 were queried for International Classification of Diseases, Ninth Revision, codes pertaining to skin cancer. Screening costs were separated from treatment costs through associated Current Procedural Terminology codes. RESULTS: The total annual cost of SCRC increased by 64%, the number of patients receiving SCRC increased by 45%, and the mean cost per patient treated increased by 13%. Screening accounted for 17% and 16% of total annual costs in 2008 and 2013, respectively. The mean cost per patient with melanoma increased by 84%, which was the largest increase among skin cancer diagnoses. In 2013, the few patients with melanoma who were treated with ipilimumab (n = 48 [4% of patients with melanoma]) accounted for 42% of melanoma treatment costs and 20% of SCRC costs. LIMITATIONS: Prescription costs were unavailable. CONCLUSIONS: Melanoma costs have increased as a result of the introduction of ipilimumab. Ongoing studies are needed to monitor the cost-effectiveness of SCRC at a national level.
引用
- Morgan FC, Duran J, Fraile B, et al. A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. J Am Acad Dermatol. 2018. PMID: 30322559. doi:10.1016/j.jaad.2018.06.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。